US5833975A
(en)
*
|
1989-03-08 |
1998-11-10 |
Virogenetics Corporation |
Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
|
US7767449B1
(en)
|
1981-12-24 |
2010-08-03 |
Health Research Incorporated |
Methods using modified vaccinia virus
|
US5174993A
(en)
*
|
1981-12-24 |
1992-12-29 |
Health Research Inc. |
Recombinant avipox virus and immunological use thereof
|
CA1340203C
(en)
*
|
1987-09-16 |
1998-12-15 |
Noboru Yanagida |
Recombinant apivoxvirus
|
CH682669A5
(fr)
*
|
1989-03-08 |
1993-10-29 |
Health Research Inc |
Virus recombinant modifié pour exprimer un produit de gènes chez un hôte, procédés et vaccin correspondants.
|
US5766598A
(en)
*
|
1991-03-07 |
1998-06-16 |
Virogenetics Corporation |
Recombinant attenuated ALVAC canarypoxvirus expression vectors containing heterologous DNA segments encoding lentiviral gene products
|
US5766597A
(en)
*
|
1991-03-07 |
1998-06-16 |
Virogenetics Corporation |
Malaria recombinant poxviruses
|
WO1992016616A1
(en)
*
|
1991-03-20 |
1992-10-01 |
Virogenetics Corporation |
Malaria recombinant poxvirus vaccine
|
US5961970A
(en)
*
|
1993-10-29 |
1999-10-05 |
Pharmos Corporation |
Submicron emulsions as vaccine adjuvants
|
WO1995011700A1
(en)
*
|
1993-10-29 |
1995-05-04 |
Pharmos Corp. |
Submicron emulsions as vaccine adjuvants
|
UA68327C2
(en)
|
1995-07-04 |
2004-08-16 |
Gsf Forschungszentrum Fur Unwe |
A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
|
EP0753581A1
(de)
*
|
1995-07-10 |
1997-01-15 |
Immuno Ag |
Verbesserte rekombinante eukaryotische zytoplasmatische Viren, Methode ihrer Herstellung und ihrer Verwendung als Impfstoffe
|
MY150893A
(en)
*
|
1996-09-24 |
2014-03-14 |
Bavarian Nordic As |
Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines
|
US20030138454A1
(en)
*
|
1997-06-09 |
2003-07-24 |
Oxxon Pharmaccines, Ltd. |
Vaccination method
|
GB9711957D0
(en)
*
|
1997-06-09 |
1997-08-06 |
Isis Innovation |
Methods and reagents for vaccination
|
US6197327B1
(en)
*
|
1997-06-11 |
2001-03-06 |
Umd, Inc. |
Device and method for treatment of dysmenorrhea
|
US6416779B1
(en)
|
1997-06-11 |
2002-07-09 |
Umd, Inc. |
Device and method for intravaginal or transvaginal treatment of fungal, bacterial, viral or parasitic infections
|
US6572874B1
(en)
|
1998-05-15 |
2003-06-03 |
Umd, Inc. |
Vaginal delivery of bisphosphonates
|
FR2766091A1
(fr)
*
|
1997-07-18 |
1999-01-22 |
Transgene Sa |
Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee
|
US6969609B1
(en)
|
1998-12-09 |
2005-11-29 |
The United States Of America As Represented By The Department Of Health And Human Serivces |
Recombinant vector expressing multiple costimulatory molecules and uses thereof
|
US6582693B2
(en)
*
|
1998-11-30 |
2003-06-24 |
Lemery, S.A. De C.V. |
Recombinant MVA virus expressing the E2 gene of Bovine papillomavirus and its use in the therapy of tumors generated by papillomaviruses
|
US20040265324A1
(en)
*
|
1999-03-23 |
2004-12-30 |
Cardosa Mary Jane |
Recombinant MVA virus expressing dengue virus antigens, and the use thereof in vaccines
|
CA2372709C
(en)
*
|
1999-05-28 |
2011-10-25 |
Stefan Wintersperger |
Vector for integration of heterologous sequences into poxviral genomes
|
US6497883B1
(en)
|
1999-06-10 |
2002-12-24 |
Merial |
Porcine circovirus recombinant poxvirus vaccine
|
EP1227837B1
(de)
|
1999-10-22 |
2008-05-21 |
Aventis Pasteur Limited |
Verfahren zur erregung und/oder verstärkung der immunantwort gegen tumorantigene
|
US8623379B2
(en)
*
|
2000-03-02 |
2014-01-07 |
Emory University |
Compositions and methods for generating an immune response
|
EP2388015A1
(de)
|
2000-03-02 |
2011-11-23 |
Emory University |
DNA-Expressionsvektoren und Verwendungsverfahren
|
US20040105871A1
(en)
*
|
2000-03-02 |
2004-06-03 |
Robinson Harriet L. |
Compositions and methods for generating an immune response
|
EP1263936B1
(de)
*
|
2000-03-14 |
2005-09-21 |
Bavarian Nordic A/S |
Veränderter stamm des modifizierten vaccinia-virus ankara (mva)
|
ES2276788T3
(es)
|
2000-05-10 |
2007-07-01 |
Sanofi Pasteur Limited |
Polipeptidos inmunogenos codificados por minigenes mage y sus utilizaciones.
|
DE10042598A1
(de)
*
|
2000-08-30 |
2002-03-28 |
Gsf Forschungszentrum Umwelt |
Rekombinantes MVA mit der Fähigkeit zur Expression des HER-2/Neu-GENS
|
US7445924B2
(en)
*
|
2000-11-23 |
2008-11-04 |
Bavarian Nordic A/S |
Modified Vaccinia Ankara virus variant and cultivation method
|
SI1335987T2
(sl)
*
|
2000-11-23 |
2016-10-28 |
Bavarian Nordic A/S |
Različica modificiranega virusa vakcinacija Ankara
|
CN1176945C
(zh)
*
|
2001-02-01 |
2004-11-24 |
中国人民解放军第二军医大学 |
疟原虫融合抗原及其制法和用途
|
ATE445411T1
(de)
*
|
2001-03-08 |
2009-10-15 |
Us Gov Health & Human Serv |
Mva-exprimierende modifizierte hiv-envelope-, gag-und pol-gene
|
UA82466C2
(uk)
*
|
2001-07-18 |
2008-04-25 |
Бавариан Нордика А/С |
Спосіб посилення ампліфікації хордопоксвірусу
|
GB0118532D0
(en)
*
|
2001-07-30 |
2001-09-19 |
Isis Innovation |
Materials and methods relating to improved vaccination strategies
|
DE10144664B4
(de)
*
|
2001-09-11 |
2005-06-09 |
GSF-Forschungszentrum für Umwelt und Gesundheit GmbH |
Vacciniavirus MVA-E3L-Knock-Out-Mutanten und Verwendung hiervon
|
DE60236364D1
(en)
|
2001-10-11 |
2010-06-24 |
Angeletti P Ist Richerche Bio |
Hepatitis-c-virus-impfstoff
|
JP2005517639A
(ja)
|
2001-11-30 |
2005-06-16 |
イシス イノベーション リミテッド |
ワクチン
|
WO2003053463A2
(en)
*
|
2001-12-10 |
2003-07-03 |
Bavarian Nordic A/S |
Poxvirus-containing compositions and process for their preparation
|
WO2003050268A2
(en)
*
|
2001-12-12 |
2003-06-19 |
Aventis Pasteur Limited |
Enhancement of the immune response using cd36-binding domain
|
US7501127B2
(en)
*
|
2002-05-16 |
2009-03-10 |
Bavarian Nordic A/S |
Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara
|
DE60320520T3
(de)
*
|
2002-09-05 |
2019-05-09 |
Bavarian Nordic A/S |
Verfahren zur amplifikation von einem poxvirus in serumfreien verhältnissen
|
AU2003297499A1
(en)
*
|
2002-12-23 |
2004-07-22 |
City Of Hope |
Modified vaccinia ankara expressing p53 in cancer immunotherapy
|
JP5052893B2
(ja)
*
|
2003-02-20 |
2012-10-17 |
アメリカ合衆国 |
ポックスベクターにおける新規の挿入部位
|
US20050175627A1
(en)
*
|
2003-09-24 |
2005-08-11 |
Oxxon Therapeutics Ltd. |
HIV pharmaccines
|
US7998733B2
(en)
|
2004-10-05 |
2011-08-16 |
Merial Limited |
Chimeric vectors
|
EP1893636A2
(de)
|
2005-06-17 |
2008-03-05 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. |
Hepatitis-c-virus-nukleinsäureimpfstoff
|
US20090060947A1
(en)
*
|
2006-05-19 |
2009-03-05 |
Sanofi Pasteur, Inc. |
Immunological compositions
|
US20080010527A1
(en)
*
|
2006-06-26 |
2008-01-10 |
Inventec Corporation |
Method of solving BIST failure of CPU by means of BIOS and maximizing system performance
|
CA2662730A1
(en)
*
|
2006-09-08 |
2008-03-13 |
Bavarian Nordic A/S |
Phenotypic and genotypic differences of mva strains
|
US7807146B2
(en)
|
2006-10-06 |
2010-10-05 |
Bn Immunotherapeutics, Inc. |
Methods for treating cancer with a recombinant MVA expressing HER-2
|
US20110165645A1
(en)
|
2008-02-12 |
2011-07-07 |
Yelin Xiong |
Methods Using Ion Exchange and Gel Filtration Chromatography for Poxvirus Purification
|
US8691502B2
(en)
|
2008-10-31 |
2014-04-08 |
Tremrx, Inc. |
T-cell vaccination with viral vectors via mechanical epidermal disruption
|
US7998488B2
(en)
|
2008-11-14 |
2011-08-16 |
Baxter International Inc. |
Vaccine formulations and uses thereof
|
CA2760315C
(en)
|
2009-04-30 |
2019-05-28 |
Centre Hospitalier Universitaire Vaudois Lausanne (Chuv) |
Modified immunization vectors
|
US20110159031A1
(en)
*
|
2009-12-22 |
2011-06-30 |
Baxter International Inc. |
Vaccine to Influenza A Virus
|
DK2529010T3
(en)
|
2010-01-28 |
2017-07-24 |
Bavarian Nordic As |
MUTANTS OF VACCINIAVIRUS CONTAINING THE MAIN GENOMIC DELETIONS OF VAT
|
AU2011224188B2
(en)
|
2010-03-12 |
2015-01-22 |
Boehringer Ingelheim Animal Health USA Inc. |
Bluetongue virus recombinant vaccines and uses thereof
|
WO2012101509A2
(en)
|
2011-01-28 |
2012-08-02 |
Sanofi Pasteur Sa |
Immunological compositions against hiv
|
WO2012151272A2
(en)
|
2011-05-02 |
2012-11-08 |
Tremrx, Inc. |
T-cell vaccination with viral vectors via mechanical epidermal disruption
|
DK2788021T3
(en)
|
2011-12-09 |
2017-04-10 |
Bavarian Nordic As |
POXVIRUS VECTOR FOR EXPRESSION OF BACTERIAL ANTIGENES CONNECTED TO TETANANOX INFRAGMENT C
|
SG11201500696VA
(en)
|
2012-08-01 |
2015-02-27 |
Bavarian Nordic As |
Recombinant modified vaccinia virus ankara (mva) respiratory syncytial virus (rsv) vaccine
|
EP2892549A1
(de)
|
2012-09-04 |
2015-07-15 |
Bavarian Nordic A/S |
Verfahren und zusammensetzungen zur verbesserung von impfstoffimmunreaktionen
|
WO2014062778A1
(en)
|
2012-10-19 |
2014-04-24 |
Bavarian Nordic, Inc. |
Methods and compositions for the treatment of cancer
|
WO2014140938A2
(en)
|
2013-03-14 |
2014-09-18 |
Centre Hospitalier Universitaire Vaudois |
Immunological methods
|
DE102013004595A1
(de)
|
2013-03-15 |
2014-09-18 |
Emergent Product Development Germany Gmbh |
RSV-Impfstoffe
|
US10801070B2
(en)
|
2013-11-25 |
2020-10-13 |
The Broad Institute, Inc. |
Compositions and methods for diagnosing, evaluating and treating cancer
|
CA2929600A1
(en)
|
2013-11-28 |
2015-06-04 |
Bavarian Nordic A/S |
Compositions and methods vectors for inducing an enhanced immune response using poxvirus vectors
|
WO2015085147A1
(en)
|
2013-12-05 |
2015-06-11 |
The Broad Institute Inc. |
Polymorphic gene typing and somatic change detection using sequencing data
|
KR20160101073A
(ko)
|
2013-12-20 |
2016-08-24 |
더 브로드 인스티튜트, 인코퍼레이티드 |
신생항원 백신과의 병용 요법
|
AU2015259516B2
(en)
|
2014-05-13 |
2020-05-28 |
Bavarian Nordic A/S |
Combination therapy for treating cancer with a poxvirus expressing a tumor antigen and a monoclonal antibody against TIM-3
|
CN107454848B
(zh)
|
2014-09-03 |
2021-06-22 |
巴法里安诺迪克有限公司 |
用于诱导针对丝状病毒感染的保护性免疫的方法和组合物
|
KR20190062617A
(ko)
|
2014-09-03 |
2019-06-05 |
버베리안 노딕 에이/에스 |
면역 반응을 증대시키기 위한 방법 및 조성물
|
EP3197489B1
(de)
|
2014-09-26 |
2021-02-17 |
Beth Israel Deaconess Medical Center, Inc. |
Verfahren und zusammensetzungen zur induzierung von schützender immunität gegen hiv-infektionen
|
US10993997B2
(en)
|
2014-12-19 |
2021-05-04 |
The Broad Institute, Inc. |
Methods for profiling the t cell repertoire
|
US10975442B2
(en)
|
2014-12-19 |
2021-04-13 |
Massachusetts Institute Of Technology |
Molecular biomarkers for cancer immunotherapy
|
PL3271729T3
(pl)
|
2015-03-18 |
2021-05-04 |
Janssen Vaccines & Prevention B.V. |
Oznaczenia systemów ekspresji rekombinowanej
|
MY190974A
(en)
|
2015-05-20 |
2022-05-25 |
Massachusetts Gen Hospital |
Shared neoantigens
|
ES2898271T3
(es)
|
2015-12-15 |
2022-03-04 |
Janssen Vaccines & Prevention Bv |
Antígenos del virus de la inmunodeficiencia humana, vectores, composiciones y métodos de uso de los mismos
|
PL3407910T3
(pl)
|
2016-01-29 |
2022-08-16 |
Bavarian Nordic A/S |
Rekombinowana zmodyfikowana szczepionka przeciwko wirusowi krowianki ankara (mva) przeciwko wirusowi zapalenia mózgu koni
|
WO2017184590A1
(en)
|
2016-04-18 |
2017-10-26 |
The Broad Institute Inc. |
Improved hla epitope prediction
|
KR102389489B1
(ko)
|
2016-06-16 |
2022-04-22 |
얀센 백신스 앤드 프리벤션 비.브이. |
Hiv 백신 제형
|
EP3484507A1
(de)
|
2016-07-15 |
2019-05-22 |
Janssen Vaccines & Prevention B.V. |
Verfahren und zusammensetzungen zur induzierung von schützender immunität gegen eine marburg-virus-infektion
|
AU2017318689A1
(en)
|
2016-09-02 |
2019-04-11 |
Beth Israel Deaconess Medical Center, Inc. |
Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
|
IL265186B
(en)
|
2016-09-15 |
2022-09-01 |
Janssen Vaccines Prevention B V |
HIV envelope proteins with trimer-stabilizing mutations
|
WO2018140391A1
(en)
|
2017-01-24 |
2018-08-02 |
The Broad Institute, Inc. |
Compositions and methods for detecting a mutant variant of a polynucleotide
|
ES2965475T3
(es)
|
2017-02-12 |
2024-04-15 |
Biontech Us Inc |
Métodos y composiciones basados en HLA y usos de los mismos
|
US11173204B2
(en)
|
2017-04-06 |
2021-11-16 |
Janssen Vaccines & Prevention B.V. |
MVA-BN and Ad26.ZEBOV or Ad26.filo prime-boost regimen
|
US11229693B2
(en)
|
2017-06-15 |
2022-01-25 |
Janssen Vaccines & Prevention B.V. |
Poxvirus vectors encoding HIV antigens, and methods of use thereof
|
BR112020000867A2
(pt)
|
2017-07-19 |
2020-07-21 |
Janssen Vaccines & Prevention B.V. |
mutações da proteína do envelope do hiv estabilizando o trímero
|
WO2019018724A1
(en)
|
2017-07-21 |
2019-01-24 |
Janssen Vaccines & Prevention B.V. |
METHODS FOR SAFE INDUCTION OF MULTICLADED CROSS-IMMUNITY AGAINST HUMAN IMMUNODEFICIENCY VIRUS INFECTION IN HUMAN BEINGS
|
WO2019055888A1
(en)
|
2017-09-18 |
2019-03-21 |
Janssen Vaccines & Prevention B.V. |
METHODS OF INDUCING AN IMMUNE RESPONSE AGAINST HUMAN IMMUNODEFICIENCY VIRUS INFECTION IN SUBJECTS UNDER ANTIRETROVIRAL TREATMENT
|
US11793867B2
(en)
|
2017-12-18 |
2023-10-24 |
Biontech Us Inc. |
Neoantigens and uses thereof
|
WO2020051766A1
(zh)
|
2018-09-11 |
2020-03-19 |
上海市公共卫生临床中心 |
一种广谱抗流感疫苗免疫原及其应用
|
US20210382068A1
(en)
|
2018-10-02 |
2021-12-09 |
Dana-Farber Cancer Institute, Inc. |
Hla single allele lines
|
WO2020131586A2
(en)
|
2018-12-17 |
2020-06-25 |
The Broad Institute, Inc. |
Methods for identifying neoantigens
|
KR20210130705A
(ko)
|
2018-12-21 |
2021-11-01 |
바이오엔테크 유에스 인크. |
Hla 클래스 ii-특이적 에피토프 예측 및 cd4+ t 세포 특징화를 위한 방법 및 시스템
|
TW202043256A
(zh)
|
2019-01-10 |
2020-12-01 |
美商健生生物科技公司 |
前列腺新抗原及其用途
|
JOP20220116A1
(ar)
|
2019-11-18 |
2023-01-30 |
Janssen Biotech Inc |
اللقاحات المستندة إلى الطافر calr وjak2 واستخداماتها
|
TW202144388A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在卵巢癌中表現之新抗原及其用途
|
TW202144389A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在多發性骨髓瘤中表現之新抗原及其用途
|
EP4135757A1
(de)
|
2020-04-13 |
2023-02-22 |
Janssen Biotech, Inc. |
Psma- und steap1-impfstoffe und ihre verwendungen
|
WO2021242793A2
(en)
|
2020-05-26 |
2021-12-02 |
The Broad Institute, Inc. |
Nucleic acid artificial mini-proteome libraries
|
EP4175721A1
(de)
|
2020-07-06 |
2023-05-10 |
Janssen Biotech, Inc. |
Prostata-neoantigene und ihre verwendungen
|
WO2022009052A2
(en)
|
2020-07-06 |
2022-01-13 |
Janssen Biotech, Inc. |
Prostate neoantigens and their uses
|
WO2022009051A1
(en)
|
2020-07-06 |
2022-01-13 |
Janssen Biotech, Inc. |
A method for determining responsiveness to prostate cancer treatment
|
AU2021400424A1
(en)
|
2020-12-14 |
2023-07-06 |
Biontech Us Inc. |
Tissue-specific antigens for cancer immunotherapy
|
WO2023076733A1
(en)
|
2021-11-01 |
2023-05-04 |
Dana-Farber Cancer Institute, Inc. |
Biologically selected nucleic acid artificial mini-proteome libraries
|
WO2023077147A2
(en)
|
2021-11-01 |
2023-05-04 |
Pellis Therapeutics, Inc. |
T-cell vaccines for patients with reduced humoral immunity
|
WO2023198815A1
(en)
|
2022-04-14 |
2023-10-19 |
Janssen Vaccines & Prevention B.V. |
Sequential administration of adenoviruses
|
US20230364227A1
(en)
|
2022-05-12 |
2023-11-16 |
Pellis Therapeutics, Inc. |
Poxvirus adjuvant for t-cell vaccination
|
WO2024011250A1
(en)
|
2022-07-08 |
2024-01-11 |
Viromissile, Inc. |
Oncolytic vaccinia viruses and recombinant viruses and methods of use thereof
|
WO2024015892A1
(en)
|
2022-07-13 |
2024-01-18 |
The Broad Institute, Inc. |
Hla-ii immunopeptidome methods and systems for antigen discovery
|